The U.S. continues to charge significantly higher prices for prescription drugs compared to similarly wealthy countries.
The stock's fall snapped a two-day winning streak.
Several large drugmakers, including Pfizer, Bristol Myers Squibb and Sanofi, increased the list prices of their drugs this month.
Dr. Robert A. Winn discusses efforts to increase diversity in clinical trials on an episode of Radio Health Journal.
Corporate borrowing surged to a record in 2024, up over a third from a year earlier as companies like AbbVie and Cisco looked ...
Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...
In 2023, drug companies launched new medications at prices 35 percent higher than the year before. On January 1, Pfizer ...
Drugmakers plan to raise US prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol ...
This was the stock's second consecutive day of gains.
Pharmaceutical companies raised the list prices of at least 250 prescriptions heading into 2025 as major changes to the ...
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $56.56 which represents a slight increase of $0.50 or 0.89% from the prior close of $56.06. The stock opened at $56.07 and ...